Scarica l'app Stockscreener
100.84
0.25%
0.25
Dopo l'orario di chiusura:
100.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$100.59
Aprire:
$100.54
Volume 24 ore:
492.86K
Relative Volume:
0.83
Capitalizzazione di mercato:
$7.83B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-25.86
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
-3.13%
1M Prestazione:
-3.93%
6M Prestazione:
+25.27%
1 anno Prestazione:
+26.07%
Intervallo 1D:
$99.42
$102.77
Intervallo di 1 settimana:
$99.38
$103.47
Portata 52W:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Confronta NUVL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
100.84 | 7.81B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
Avoiding Lag: Real-Time Signals in (NUVL) Movement - Stock Traders Daily
Bear Alert: How Nuvalent Inc stock performs in weak economyWeekly Stock Analysis & Daily Profit Maximizing Tips - moha.gov.vn
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
PRN_FinancialWrapper | PR NewswireNuvalent, Inc.Class A Common Stock (Nasdaq:NUVL) Stock Quote - FinancialContent
Nuvalent Earnings Notes - Trefis
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
3 Biotech Stocks With Major 2026 Catalysts - TradingView — Track All Markets
Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Nuvalent files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Technical Reactions to NUVL Trends in Macro Strategies - Stock Traders Daily
What drives Nuvalent Inc stock priceStock Buyback Updates & Follow Top Performers in the Community - earlytimes.in
Why Nuvalent Inc. stock remains a top recommendationJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Улправда
Can Nuvalent Inc. stock reach $100 price target2025 Big Picture & Proven Capital Preservation Methods - Улправда
JPMorgan Chase & Co. Lowers Nuvalent (NASDAQ:NUVL) Price Target to $145.00 - MarketBeat
Aug Sentiment: Is Nuvalent Inc. stock a defensive play in 2025Weekly Loss Report & Community Trade Idea Sharing Platform - DonanımHaber
Is Nuvalent Inc. stock a defensive play in 20252025 Key Lessons & Daily Stock Momentum Reports - DonanımHaber
JP Morgan Lowers Target Price for Nuvalent (NUVL) to $145 | NUVL Stock News - GuruFocus
Certain Restricted Stock Units of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Certain Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
66,836,884 Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Canada
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - The Globe and Mail
Nuvalent Acknowledges Royalty Pharma's Acquisition of Royalty Interest - TradingView — Track All Markets
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
Nuvalent (NUVL) director discloses RSU and stock option acquisitions - Stock Titan
Nuvalent, Inc. (NUVL) is a buy on lung cancer treatment prospects - MSN
HighVista Strategies LLC Has $3.85 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent appoints Ron Squarer to board of directors By Investing.com - Investing.com Nigeria
Ron Squarer Joins Nuvalent Board as Independent Director - The Globe and Mail
Trading the Move, Not the Narrative: (NUVL) Edition - news.stocktradersdaily.com
Insider Sell Alert: Alexandra Balcom Sells Shares of Nuvalent In - GuruFocus
Nuvalent Appoints Ron Squarer to Board of Directors - GuruFocus
Nuvalent appoints Ron Squarer to board of directors - Investing.com
Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing - marketscreener.com
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):